Halozyme (RV7) Financial Statements
Halozyme Financial Overview
Halozyme's market cap is currently $12.24B. The company's EPS TTM is $3.52; its P/E ratio is 37.19; Halozyme is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $1.89. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.40B | $ 1.02B | $ 829.25M | $ 660.12M | $ 443.31M |
| Gross Profit | $ 1.17B | $ 855.91M | $ 636.89M | $ 520.81M | $ 361.90M |
| Operating Income | $ 802.59M | $ 551.48M | $ 337.57M | $ 267.53M | $ 275.90M |
| EBITDA | $ 573.05M | $ 656.54M | $ 451.95M | $ 315.51M | $ 259.04M |
| Net Income | $ 316.89M | $ 444.09M | $ 281.59M | $ 202.13M | $ 402.71M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 142.82M | $ 596.07M | $ 336.00M | $ 362.79M | $ 740.92M |
| Total Assets | $ 2.53B | $ 2.06B | $ 1.73B | $ 1.84B | $ 1.10B |
| Total Debt | $ 2.14B | $ 1.51B | $ 1.50B | $ 1.51B | $ 876.67M |
| Net Debt | $ 2.01B | $ 1.39B | $ 1.38B | $ 1.27B | $ 757.96M |
| Total Liabilities | $ 2.48B | $ 1.70B | $ 1.65B | $ 1.67B | $ 907.48M |
| Stockholders' Equity | $ 48.81M | $ 363.82M | $ 83.81M | $ 169.80M | $ 196.95M |
| Cash Flow | |||||
| Free Cash Flow | $ 644.59M | $ 468.37M | $ 373.28M | $ 235.30M | $ 297.98M |
| Operating Cash Flow | $ 651.56M | $ 479.06M | $ 388.57M | $ 240.11M | $ 299.44M |
| Investing Cash Flow | $ -545.81M | $ -262.72M | $ -96.91M | $ -487.00M | $ -406.29M |
| Financing Cash Flow | $ -85.17M | $ -218.86M | $ -407.99M | $ 362.37M | $ 77.86M |
Currency in USD